AtriCure price target raised to $57 from $53 at BTIG

BTIG raised the firm’s price target on AtriCure (ATRC) to $57 from $53 and keeps a Buy rating on the shares. The company’s Q4 revenue was in line with its pre-announcement last month, though revenue in U.S. and outside U.S. both exceeded estimates, driven by strength in the U.S. cryoSPHERE pain management segment, U.S. and Outside US open AtriClip businesses, and U.S. EnCompass clamp franchise, the analyst tells investors in a research note.